(Q53567620)

15 May 2018

title

The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice. (English)

1 reference

15 May 2018

1 reference

Jinah Hwang

1

1 reference

15 May 2018

Dean J Kleinhenz

2

1 reference

15 May 2018

Heidi L Rupnow

3

1 reference

15 May 2018

Adam G Campbell

4

1 reference

15 May 2018

Peter M Thulé

5

1 reference

15 May 2018

Roy L Sutliff

6

1 reference

15 May 2018

C Michael Hart

7

1 reference

15 May 2018

publication date

8 February 2007

1 reference

15 May 2018

published in

Vascular Pharmacology

1 reference

15 May 2018

volume

46

1 reference

15 May 2018

issue

6

1 reference

15 May 2018

page(s)

456-462

1 reference

15 May 2018

Superoxide-NO interaction decreases flow- and agonist-induced dilations of coronary arterioles in Type 2 diabetes mellitus

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Peroxisome proliferator-activated receptor gamma (PPARgamma) activation and its consequences in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Impaired endothelium-mediated relaxation in isolated cerebral arteries from insulin-resistant rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Troglitazone, an insulin sensitizer, increases forearm blood flow in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Diabetes, a New Mutation in the Mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Oscillatory shear stress stimulates endothelial production of O2- from p47phox-dependent NAD(P)H oxidases, leading to monocyte adhesion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Diabetes trends in the U.S.: 1990-1998.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db -/-) mice: role of decreased tetrahydrobiopterin bioavailability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Superoxide production and expression of nox family proteins in human atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Diabetes, hypertension, and cardiovascular disease: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Regulation of adipogenesis and energy balance by PPARgamma and PGC-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Antioxidative, Antinitrative, and Vasculoprotective Effects of a Peroxisome Proliferator–Activated Receptor-γ Agonist in Hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

Induction of the rat Cu/Zn superoxide dismutase gene through the peroxisome proliferator-responsive element by arachidonic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2007.01.007

10.1016/J.VPH.2007.01.007

7 January 2021

Identifiers

DOI

1 reference

15 May 2018

1 reference

15 May 2018